non responder to glp 1 GLP-1 Agonists and the Non-Responder Problem: What We Know, What We Assume, and What Why Some Patients Do Not – Understanding GLP-1 Non-Responders: Key Insights

She has been part of Medical Dialogues since March 2021.

Hcy is implicated in cardiovascular disease through diverse mechanisms, including the heightened proliferation of muscle cells leading to vessel constriction, modification of blood coagulation properties, oxidative damage to the vascular endothelium, and harm to arterial walls [49]

Potential protective strategies, including NMDA receptor antagonists, are under investigation to prevent glutamate-mediated cochlear damage (Fu et al

The possible function of SULTR1;2 (Zhang et al., 2014) as a sulfate sensor is intriguing, particularly as the Chlamydomonas regulator of S-starvation response, SAC1, is similar to SULTR of the SLC13 group (Takahashi et al., 2011a)

Study protocol and informed consent, according to the Helsinki Declaration of 1975, version 2008 41 , were approved by the Regional Committee for Medical and Health Research Ethics (REC, Health Region West) (2012/2212), University of Bergen, Norway

Prescribing of AOM tirzepatide (brand name Zepbound) was observed in the first month of availability in pharmacies, December 2023